No image published for this recall

No image published for this recall

Vitros eci immunodiagnostic intact pth reagent

Official notice

2 Dec 2022

Last checked

2 Dec 2022

Medium riskHealth Canada

An official Health Canada notice concerns Vitros eci immunodiagnostic intact pth reagent. Ortho received 166 world-wide complaints for Vitros iPTH reagent pack related to observations of lower-than-expected iPTH patient and quality control (QC) results with the affected lots listed above. Customers reported the negatively biased iPTH results when comparing results produced from the affected reagent lots to results produced from unaffected lots for patient correlation testing as well as assessing QC results from Biorad and Thermo Fisher. Ortho's investigation compared results produced from affected reagent lots to results produced from unaffected reagent lots and confirmed an average -12% shift in patient sample results. Ortho's investigation included 119 patient samples, with patient sample concentrations ranging from 10 pg/ml - 2391 pg/ml, with the highest bias observed on an individual sample at approximately -26.7% and an overall estimated average bias of approximately -12%. A variable negative shift in performance was also confirmed using Biorad Liquicheck/Lyphocheck Specialty Immunoassay controls and Thermo Scientific Mas Omni Immune Immunoassay controls when compared to their published assigned values. Vitros Immunodiagnostic products iPTH controls do not detect this bias, therefore no performance shifts of the controls were observed. Recall start date: November 18, 2022 Published 2022-12-02.

What to do now

Contact the manufacturer if you require additional information.

Recall number

72232

Official notice

2022-12-02

The hazard

Ortho received 166 world-wide complaints for Vitros iPTH reagent pack related to observations of lower-than-expected iPTH patient and quality control (QC) results with the affected lots listed above. Customers reported the negatively biased iPTH results when comparing results produced from the affected reagent lots to results produced from unaffected lots for patient correlation testing as well as assessing QC results from Biorad and Thermo Fisher. Ortho's investigation compared results produced from affected reagent lots to results produced from unaffected reagent lots and confirmed an average -12% shift in patient sample results. Ortho's investigation included 119 patient samples, with patient sample concentrations ranging from 10 pg/ml - 2391 pg/ml, with the highest bias observed on an individual sample at approximately -26.7% and an overall estimated average bias of approximately -12%. A variable negative shift in performance was also confirmed using Biorad Liquicheck/Lyphocheck Specialty Immunoassay controls and Thermo Scientific Mas Omni Immune Immunoassay controls when compared to their published assigned values. Vitros Immunodiagnostic products iPTH controls do not detect this bias, therefore no performance shifts of the controls were observed. Recall start date: November 18, 2022

How to check if you're affected

Compare the product name and identifiers below with the item you own. Follow the official notice if they match.

Recall Numbers

72232

Lots

confirmed

Checked manually this time?

The app alerts you when a new official recall is published — no searching, no checking back.

Turn on recall alerts

Affected products

Product 1

Affected products - Vitros ECi Immunodiagnostic Intact PTH Reagent, Lot or serial number - 1610 1621 1640 1650 1645 1630 1670, Model or catalog number - 680 2892

Risk / hazard

Ortho received 166 world-wide complaints for Vitros iPTH reagent pack related to observations of lower-than-expected iPTH patient and quality control (QC) results with the affected lots listed above. Customers reported the negatively biased iPTH results when comparing results produced from the affected reagent lots to results produced from unaffected lots for patient correlation testing as well as assessing QC results from Biorad and Thermo Fisher. Ortho's investigation compared results produced from affected reagent lots to results produced from unaffected reagent lots and confirmed an average -12% shift in patient sample results. Ortho's investigation included 119 patient samples, with patient sample concentrations ranging from 10 pg/ml - 2391 pg/ml, with the highest bias observed on an individual sample at approximately -26.7% and an overall estimated average bias of approximately -12%. A variable negative shift in performance was also confirmed using Biorad Liquicheck/Lyphocheck Specialty Immunoassay controls and Thermo Scientific Mas Omni Immune Immunoassay controls when compared to their published assigned values. Vitros Immunodiagnostic products iPTH controls do not detect this bias, therefore no performance shifts of the controls were observed. Recall start date: November 18, 2022

Where it was sold

The source does not list specific retailers. See the official notice for where affected products were sold.

Location 1

CA · Canada

Affected area 1

CA · Canada

Company & contacts

Brand: Ortho-clinical Diagnostics, Vitros Eci Immunodiagnostic Intact Pth Reagent.

Source & status

Source

Health Canada

Tier

official

Category

HOME

Classification

Type II

App estimate

medium

Recall details

Recall number

72232

Classification

Type II

Source tier

official

Documents, notices & source

See the official notice and source documents for full details.

View full official notice
Something wrong on this page?

Weekly recall digest

Get next week's recalls before you need them.

One email every Monday — official-source recalls for your country, and nothing else. Unsubscribe from any email.

The digest is the slow lane — one email a week. For instant, severity-gated alerts the moment a notice is published, get the app.

This recall was published 2 Dec 2022. The next one won't wait for you to search.

RecallScope watches official sources for the brands and VINs you follow, and alerts you the moment a new notice is published.